

FORM PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
P28604Application No.
10/551,780INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)Applicant
Motoharu SEIKI et al.Filing Date
October 3, 2005Group
1642

U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPRO.)

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS

	DOCUMENT (Including Author, Title, Date, Pertinent Pages, Etc.)
/MH/	Hatakeyama H et al.; "Tumor targeting of doxorubicin by anti-MT 1-MIVIP antibody-modified PEG liposomes." Int. J. Pharm. 342(1-2): 194-200 (2007). Epub 2007 May 10.
/MH/	Atobe K et al.; "In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP)." Biol. Pharm. Bull. 30(5): 972-8 (2007).
/MH/	Abstracts of the 20th annual meeting of the Academy of Pharmaceutical Science and Technology, Japan (2005), Kobayashi H et al., "Study on formulation of anti-MT1-MMP antibody-bound liposome-Optimization of binding amount of antibody-" accompanied by an English Translation.

EXAMINER

/Mark Halvorson/

DATE CONSIDERED

06/28/2011

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.